Around 15–20% of all breast cancers overexpress the HER2 receptor, many of them due to the amplification of the ERBB2 gene on chromosome 17, and HER2-driven cancers are generally aggressive46,47. This evidence concerns the gene ERBB2 and breast carcinoma.